drugset / Trial / NCT07266493
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2
Recruiting
26 enrolled
Shanghai Zhongshan Hospital
Jiangsu Simcere Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This single center, prospective, single arm clinical study aims to evaluate the clinical efficacy and safety of Envafolimab combined with albumin bound paclitaxel and carboplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2026-06-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Envafolimab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |